Yajun Liu obtained her Bachelor of Science in 2014 at the Hunan University in China. She was awarded a grant by Student Innovation Training Program to explore the biological effects of two p53 gene mutations in tumour cells. She achieved her Master’s Degree in Biotechnology Research Extensive at the University of Queensland in 2018. In between 2017 and 2018, she worked on developing a novel nanocomposite that targets macrophage for the treatment of atherosclerosis in the Australian Institute for Bioengineering and Nanotechnology and the Pharmacy Australia Centre of Excellence. She published her research findings on ACS Applied Bio Materials as the first author in 2019. Her research on nanomaterial interactions with macrophages sparked her interest in macrophage biology and innate immunity against infections. This led to her join the Hume lab as a PhD student at the Mater Research Institute – University of Queensland. She is currently focusing on understanding the transcriptional regulation of Csf1r gene that provides a model for macrophage-specific expression.